EC

Epiphron Capital

North America, New Jersey, United States, North Bergen

Description

Epiphron Capital is an investment firm focused on a healthcare investment fund.

Investor Profile

Epiphron Capital has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (100%)

Country Focus

  • China (67%)
  • United States (33%)

Industry Focus

  • Biotechnology
  • Health Care
  • Biopharma
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Epiphron Capital frequently co-invest with?

East Post Road Ventures
North America, New York, United States, White Plains
Co-Investments: 1
Hillhouse Investment
Asia, Central Region, Singapore, Singapore
Co-Investments: 2
Co-Investments: 2
AC
Asia, Hong Kong Island, Hong Kong, Central
Co-Investments: 1
3W Capital
North America, Ontario, Canada, Toronto
Co-Investments: 1
T4
North America, Michigan, United States, Lansing
Co-Investments: 1
Adjuvant Capital
North America, New York, United States, New York
Co-Investments: 1
Northwell Ventures
North America, New York, United States, New Hyde Park
Co-Investments: 1
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
P5 Health Ventures
North America, Connecticut, United States, Fairfield
Co-Investments: 1

What are some of recent deals done by Epiphron Capital?

Clarapath

New York, New York, United States

Clarapath is a medical robotics company that develops the SectionStar, a platform to mimic the human histotechnician.

BiotechnologyHealth CareMedical
Series BNov 17, 2021
Amount Raised: $16,000,000
YS Biopharma

Beijing, Beijing, China

YS Biopharma is a global, fully integrated bio-pharmaceutical company.

BiopharmaBiotechnologyHealth Care
Series BFeb 24, 2021
Amount Raised: $130,000,000
Transcenta

Huangpu, Shanghai, China

Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.

BiopharmaBiotechnology
Series BJan 8, 2020
Amount Raised: $100,000,000